← Adaptive Biotechnologies Corp
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($42.8m) | ($46.4m) | ($68.6m) | ($146.2m) | ($207.3m) | ($200.4m) | ($225.3m) | ($159.6m) | ($59.5m) | — | |
| Depreciation expense | $4.1m | $4.3m | $6.1m | $6.8m | $12.3m | $19.2m | $20.5m | $17.6m | $16.1m | $18.3m | |
| Intangible assets amortization | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | — | |
| Investment amortization | $342k | ($1.2m) | ($4.5m) | $773k | $7.2m | $741k | ($9.2m) | ($8.2m) | ($2.5m) | — | |
| Share-based compensation expense | $7.0m | $11.1m | $13.1m | $24.8m | $43.3m | $55.5m | $62.9m | $53.6m | $51.5m | $51.9m | |
| Impairment of long-lived assets | — | — | — | — | — | — | $25.4m | $7.2m | $0 | — | |
| Accounts receivable, net | ($2.4m) | $775k | ($7.8m) | $2.6m | ($7.4m) | ($22.6m) | $2.0m | ($3.7m) | ($8.6m) | ($8.7m) | |
| Write-off of inventory | — | — | — | — | — | — | $1.4m | $1.9m | $563k | — | |
| Inventory | ($2.7m) | ($3.0m) | ($1.2m) | ($5.0m) | ($5.2m) | $817k | ($2.8m) | $5.4m | ($998k) | $5.4m | |
| Accounts payable and accrued liabilities | ($1.5m) | $2.2m | $6.1m | $7.5m | $3.9m | $7.1m | ($5.4m) | $671k | $665k | — | |
| Purchases of equipment included in accounts payable and accrued liabilities | $41k | $832k | $773k | $4.7m | $682k | $1.7m | $687k | $1.3m | $509k | — | |
| Deferred revenue | $2.5m | ($649k) | $266.9m | ($43.4m) | ($57.7m) | ($56.5m) | ($29.3m) | ($10.5m) | ($36.7m) | — | |
| Other | ($15k) | ($20k) | ($12k) | ($276k) | ($275k) | $169k | ($73k) | $27k | $142k | — | |
| Prepaid expenses and other current assets | ($327k) | ($318k) | ($8.6m) | ($1.4m) | $1.3m | $3.6m | ($1.9m) | $83k | ($1.7m) | — | |
| Net cash used in operating activities | ($34.9m) |
($32.3m)
+7.46%
|
$205.4m
+736.73%
|
($149.7m)
-172.87%
|
($192.7m)
-28.76%
|
($183.9m)
+4.56%
|
($156.3m)
+15.02%
|
($95.2m)
+39.09%
|
($46.0m)
+51.70%
|
($80.5m)
-74.99%
|
|
| Purchases of property and equipment | ($2.4m) | ($6.3m) | ($11.2m) | ($18.8m) | ($61.7m) | ($16.3m) | ($10.7m) | ($3.7m) | ($3.0m) | ($2.3m) | |
| Purchases of marketable securities | ($125.2m) | ($146.5m) | ($884.2m) | ($695.0m) | ($316.5m) | ($278.8m) | ($429.6m) | ($244.3m) | ($181.7m) | — | |
| Proceeds from maturities of marketable securities | $163.9m | $153.5m | $413.7m | $596.7m | $559.5m | $298.0m | $569.9m | $325.7m | $222.6m | — | |
| Net cash provided by investing activities | $36.4m | $736k | ($481.7m) | ($117.0m) | $181.2m | $2.9m | $129.6m | $77.8m | $38.0m | $56.3m | |
| Cash provided by financing activities | $50.0m |
$1.2m
-97.51%
|
$319.9m
+25534.29%
|
$293.6m
-8.23%
|
$27.1m
-90.75%
|
$132.3m
+387.24%
|
$2.2m
-98.30%
|
$241k
-89.27%
|
$30.4m
+12515.35%
|
— | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $51.6m | ($30.3m) | $43.6m | $26.9m | $15.6m | ($48.8m) | ($24.4m) | ($17.2m) | $22.4m | — | |
| Cash, cash equivalents and restricted cash at beginning of year | $85.4m | $55.1m | $98.7m | $125.6m | $141.2m | $92.4m | $68.0m | $50.8m | $73.2m | — | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Noncash lease expense | — | — | — | $3.3m | $7.0m | $7.2m | $6.9m | $5.3m | $5.4m | — | |
| Revenue interest purchase agreement interest | — | — | — | — | — | — | $5.3m | $2.6m | ($2.1m) | — | |
| Noncash interest expense | — | — | — | — | — | $985k | $5.3m | $2.6m | — | — | |
| Operating lease right-of-use assets and liabilities | — | — | — | ($886k) | $8.5m | ($4.0m) | ($8.7m) | ($9.4m) | ($10.5m) | — | |
| Proceeds from exercise of stock options | $222k | $1.3m | $4.1m | $21.7m | $26.7m | $7.9m | $2.2m | $241k | $17.9m | — | |
| Proceeds from capital contributions for Digital Biotechnologies, Inc. | — | — | — | — | $429k | — | $0 | $0 | $12.5m | — | |
| Cash paid for interest | — | — | — | — | — | $494k | $9.0m | $8.9m | $12.6m | — |